california dmhc glp-1 coverage exclusion allowed GLP-1s in 2026: What Brokers Need to Know california dmhc glp-1 coverage exclusion

Retatrutide vs Tirzepatide: Key Differences Explained Retatrutide vs tirzepatide: compare mechanisms, clinical trial results, FDA status, and safety data in this evidence-based 2026 guide

Most patients remain on the same maintenance dose for months or years without needing increases

On September 18th, we hosted an in-depth webinar exploring the role anti-obesity medications like GLP-1 agonists can play in reshaping chronic condition management, specifically within employer-sponsored health plans

Aproximadamente 1 de cada 8 personas en el pas usa medicamentos GLP-1 para la diabetes, prdida de peso y otras enfermedades crnicas, incluyendo semaglutida (Ozempic, Wegovy) o tirzepatida (Mounjaro, Zepbound)

Treatment is guided by the same Utah-based MD, with personalized dosing, side-effect support, and long-term weight management focused on safe, sustainable weight loss

The diagnosis involves a multifaceted approach, including clinical evaluation, laboratory tests, and additional investigations if necessary